The results suggest the drug boasts similar safety and efficacy in non-small cell lung cancer compared with the field’s ...
According to the latest market analysis by Future Market Insights, the global vascular endothelial growth factor inhibitor ...
Ocular Therapeutix has initiated a long-term extension trial evaluating the investigational intravitreal therapy AXPAXLI in ...
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
At the 131st Congress of the French Society of Ophthalmology in Paris, France, the role of second-generation intravitreal anti-VEGF injections compared to corticosteroid injections in treating ...
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...
The phase 3 CONDOR trial found brolucizumab superior to panretinal laser photocoagulation for proliferative diabetic retinopathy, offering better vision outcomes and disease regression. The anti-VEGF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results